QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers

Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied...

Descripción completa

Detalles Bibliográficos
Autores principales: Brener, Oleksandr, Dunkelmann, Tina, Gremer, Lothar, van Groen, Thomas, Mirecka, Ewa A., Kadish, Inga, Willuweit, Antje, Kutzsche, Janine, Jürgens, Dagmar, Rudolph, Stephan, Tusche, Markus, Bongen, Patrick, Pietruszka, Jörg, Oesterhelt, Filipp, Langen, Karl-Josef, Demuth, Hans-Ulrich, Janssen, Arnold, Hoyer, Wolfgang, Funke, Susanne A., Nagel-Steger, Luitgard, Willbold, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585794/
https://www.ncbi.nlm.nih.gov/pubmed/26394756
http://dx.doi.org/10.1038/srep13222
Descripción
Sumario:Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer´s disease.

Ejemplares similares